In the hormone receptor positive setting, the Saci-IO HR+ trial is enrolling patients in a phase II study of sacituzumab govitecan with or without pembrolizumab in patients with metastatic HR+/HER2- breast cancer (NCT04448886). This evidence concerns the gene NR4A1 and breast cancer.